Mesoblast Limited (MESO) is a Biotechnology company in the Healthcare sector, currently trading at $14.61. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is MESO = $12 (-21.3% upside).
Valuation: MESO trades at a trailing Price-to-Earnings (P/E) of -23.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.17.
Financials: revenue is $17M, +47.8%/yr average growth. Net income is $102M (loss), growing at -4.4%/yr. Net profit margin is -593.9% (negative). Gross margin is 70.2% (+592.8 pp trend).
Balance sheet: total debt is $128M against $597M equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 1.99 (strong liquidity). Debt-to-assets is 16.3%. Total assets: $785M.
Analyst outlook: 5 / 11 analysts rate MESO as buy (45%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
